A phase 1 trial published in Nature Medicine shows that 10E8.4/iMab, a bispecific monoclonal antibody, is safe and well tolerated in both HIV-positive and HIV-negative individuals, supporting advancement to efficacy trials. This dual-targeting approach could offer a single therapy for both HIV prevention and treatment. โ Photo by Miguel ร. Padriรฑรกn on Pexels (Pexels License)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accrรฉditation Sans Frontiรจres (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016โ2021). ORCID: 0000-0001-7609-4515.
